An interventional study of Telemedicine Barbershop BP Reduction in Antihypertensive Agents, High Blood Pressure and Hypertension, sponsored by Cedars-Sinai Medical Center. Not yet recruiting at 1 site in United States. Open to male participants aged 35 Years to 79 Years. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Cedars-Sinai Medical Center · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Hypertension by Cedars-Sinai Medical Center — 1 open to participants now, 1 under way, none of them phase 3. Hypertension · Cedars-Sinai Medical Center.
Among the 14 studies in Hypertension by Cedars-Sinai Medical Center, this one is the 4th largest by planned enrollment of the 12 interventional ones that give a count, is the only one that started in 2026, is one of 9 with no phase, and was the 14th registered.
6,128 studies on the registry are indexed under Hypertension; 907 are open to participants now.
Browse Hypertension studies →1 of the 14 studies in Hypertension by Cedars-Sinai Medical Center is open now, in 1 country.
By country, each count listing its studies:
Of the 552 Hypertension studies recruiting now, 260 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 136 take healthy volunteers.
This study: 35 Years to 79 Years · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2006; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 55 is below the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 40 across the 12 interventional studies, 30 across the 2 observational. Of the 10 that completed or were terminated, 2 (20%) have results posted.
This tab as a report to print or save as PDF → With an account.
Cedars-Sinai Medical Center is the lead sponsor of 457 studies on the registry; 108 are open to participants now.
Of its 65 completed or terminated interventional studies of FDA-regulated products, 49 (75%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 14 studies in Hypertension by Cedars-Sinai Medical Center, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged. The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men." It will build upon the foundational work of the original study and telemedicine pilot by evaluating the efficacy of a fully remote hypertension management program.
The original, "Cut Your Pressure Too: The LA Barbershop Blood Pressure Study (LABBPS)" (NCT02321618) was a highly successful cluster-randomized trial of a community centered blood pressure (BP) reduction program focused on Non-Hispanic (NH) black men who experience the highest rates of hypertension (HTN) and its complications. Patrons of 52 barbershops in Los Angeles County were randomly assigned to either an intervention arm in which barbers encouraged meetings with trained clinical pharmacists who provided HTN treatment in the barbershops or a control arm in which barbers provided educational pamphlets on HTN and encouraged physician appointments. After 6 months, the intervention group had a statistically significant reduction in systolic BP (SBP) of 21.6 mmHg compared to the control group. Results were durable at 1 year. Thereafter, a pilot study (NCT03726710) aimed at improving the efficiency of the barbershop model of HTN care by substituting in-person visits with video visits once BP was at goal was undertaken in 10 hypertensive barbershop patrons. The intervention effect was unchanged.
The current study represents Aim 3 of an NIH funded renewal application entitled, "Barber and Pharmacist Coordination to Improve Blood Pressure Management in Black Men". The goal of the study is to build upon the foundational work of the original study and adapt the in-person clinical pharmacist-led LABBPS hypertension (HTN) management program into a complete telemedicine version and assess feasibility, acceptability, effectiveness, and implementation considerations of the adaptation to inform future scale-up. We will design and test the impact of barber assisted hypertension screening combined with clinical pharmacist-led hypertension management delivered via a secure video platform among 55 men from 10 barbershops. Participants will be age 35-79 years with stage 2 hypertension defined as systolic blood pressure ≥ 140 mm Hg and/or diastolic blood pressure ≥ 90 mm Hg. This diverse age group was chosen because current guidelines recommend initiation of antihypertensive medications for stage 2 hypertension regardless of baseline cardiovascular risk. In addition to using validated implementation science frameworks to measure feasibility and acceptability, the study will also quantify effectiveness by comparing changes in blood pressure at 6-months to those achieved in the original in-person intervention.
Hypertension (HTN) is an exceptionally common condition that imposes a substantial public health burden and disproportionately impacts non-Hispanic (NH) Black men. The Barber and Pharmacist Coordination to Improve Blood Pressure Management Study builds upon the foundational work of the Los Angeles Barbershop BP Study (ClinicalTrials.gov ID: NCT02321618) and seeks to develop a less costly and more convenient telemedicine version of pharmacist-driven, community-based hypertension care for black men that will enable widespread adoption of this healthcare model across barbershops nationwide. While the barbershop-based approach has demonstrated success in non-Hispanic black men, the benefits may well extend to other racial and ethnic populations who frequent community- based venues. Increasing adoption of community-based interventions and enabling supportive healthcare policies requires the demonstration of a financially feasible model and durable impact on clinical outcomes.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Test feasibility, acceptability, and effectiveness of an adapted blood pressure reduction intervention that moves the LABBPS in-person clinical pharmacist to a telemedicine platform inside of the barbershop.
Change in Systolic Blood Pressure (SBP)
The primary outcome will be the difference in SBP measured at 6 months compared to enrollment.
Time frame: 6 months
Change in Diastolic Blood Pressure (DBP)
1. Difference in DBP measured at 6 months compared to enrollment 2. Achievement of goal BP, 6 months, Proportion of participants achieving SBP \<130 mm Hg AND DBP \<80 mm Hg 3. Medication Intensification, 6 months, Difference in the number of BP drugs of different classes at 6 months compared to enrollment 4. First-line medication use, 6 months, Difference in percentage of participants receiving first-line BP drug classes at 6 months compared to enrollment 5. Recruitment and retention rates will be quantified to assess feasibility 6. Acceptability to barbers and participants
Time frame: 6 months
Plan to share: No
Start is estimated for Oct 2026; primary completion for Oct 2028, 24 months later.
Of 1,407 non-industry interventional studies with no phase under Hypertension, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 41. This study's planned 24 months is close to that.
Counting every sponsor, half of 1,502 studies reached it within 23 months; a quarter within 10 and three quarters within 42.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.